Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics develops personalized immune therapies for cancer using the DCVax platform technology. Lead product DCVax-L treats Glioblastoma multiforme brain cancer after completing Phase III clinical trials. Another product, DCVax-Direct, is in Phase I/II trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Overview
Strengths
- Creates economic value: ROIC of 100.0% against a cost of capital (WACC) of 4.9%, a spread of 95.1 percentage points.
- ROIC of 100.0% beats 93% of its 128 Biotechnology peers (median 0.0%).
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 13.3% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Unstable profitability: operating margin ranged from -6,708% to -2,873% over the last 6 years, with operating losses in 6 of them.
Key Financial Data